CA2890042C - 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives - Google Patents

1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives Download PDF

Info

Publication number
CA2890042C
CA2890042C CA2890042A CA2890042A CA2890042C CA 2890042 C CA2890042 C CA 2890042C CA 2890042 A CA2890042 A CA 2890042A CA 2890042 A CA2890042 A CA 2890042A CA 2890042 C CA2890042 C CA 2890042C
Authority
CA
Canada
Prior art keywords
pyrrolidine
benzoyl
carbonyl
carbonitrile derivatives
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2890042A
Other languages
English (en)
French (fr)
Other versions
CA2890042A1 (en
Inventor
Ernest Giralt Lledo
Teresa Tarrago Clua
Roger PRADES COSANO
Soledad Royo Gracia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de Barcelona UB
Fundacio Privada Institut de Recerca Biomedica IRB
Accure Therapeutics SL
Original Assignee
Universitat de Barcelona UB
Fundacio Privada Institut de Recerca Biomedica IRB
Accure Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat de Barcelona UB, Fundacio Privada Institut de Recerca Biomedica IRB, Accure Therapeutics SL filed Critical Universitat de Barcelona UB
Publication of CA2890042A1 publication Critical patent/CA2890042A1/en
Application granted granted Critical
Publication of CA2890042C publication Critical patent/CA2890042C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Epidemiology (AREA)
CA2890042A 2012-11-12 2013-11-11 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives Active CA2890042C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382446.8 2012-11-12
EP12382446.8A EP2730571A1 (en) 2012-11-12 2012-11-12 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
PCT/EP2013/073460 WO2014072498A1 (en) 2012-11-12 2013-11-11 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Publications (2)

Publication Number Publication Date
CA2890042A1 CA2890042A1 (en) 2014-05-15
CA2890042C true CA2890042C (en) 2021-06-01

Family

ID=47278735

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2890042A Active CA2890042C (en) 2012-11-12 2013-11-11 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Country Status (25)

Country Link
US (2) US10125097B2 (enExample)
EP (2) EP2730571A1 (enExample)
JP (1) JP6203278B2 (enExample)
KR (1) KR102151290B1 (enExample)
CN (1) CN104903314B (enExample)
AU (1) AU2013343430B2 (enExample)
BR (1) BR112015010377A8 (enExample)
CA (1) CA2890042C (enExample)
CY (1) CY1118818T1 (enExample)
DK (1) DK2917209T3 (enExample)
EA (1) EA028422B1 (enExample)
ES (1) ES2621672T3 (enExample)
HR (1) HRP20170485T1 (enExample)
HU (1) HUE032472T2 (enExample)
LT (1) LT2917209T (enExample)
ME (1) ME02706B (enExample)
MX (1) MX367488B (enExample)
NZ (1) NZ709096A (enExample)
PL (1) PL2917209T3 (enExample)
PT (1) PT2917209T (enExample)
RS (1) RS55865B1 (enExample)
SI (1) SI2917209T1 (enExample)
SM (1) SMT201700202T1 (enExample)
WO (1) WO2014072498A1 (enExample)
ZA (1) ZA201504269B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2730571A1 (en) 2012-11-12 2014-05-14 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
EP3031458A1 (en) * 2014-12-09 2016-06-15 Iproteos S.L. Use of 1-[(2-phenylcycloprop-1-yl)carbonyl]-2-[(1,3-thiazolidin-3-yl)carbonyl]perhydroindole in the treatment of schizophrenia-associated cognitive deficits
SG11202005563YA (en) 2017-12-15 2020-07-29 Praxis Biotech LLC Inhibitors of fibroblast activation protein
JP2022514352A (ja) 2018-12-21 2022-02-10 プラクシス バイオテック エルエルシー 線維芽細胞活性化タンパク質の阻害剤
EP4178945B1 (en) * 2020-07-07 2024-08-28 Accure Therapeutics, S.L. 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
MY208099A (en) 2020-12-28 2025-04-15 Sarawak Biodiversity Council Compound for treating neurodegenerative diseases and its isolation method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018891A1 (en) * 1990-06-04 1991-12-12 Pfizer Inc. Aromatic pyrrolidine and thiazolidine amides
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
HUT76640A (en) * 1995-08-17 1997-10-28 Chinoin Gyogyszer Es Vegyeszet Compounds of pharmaceutical activity cyclic amide derivatives, pharmaceutical compositions containing them, process for producing them and their use
DE19603510A1 (de) 1996-02-01 1997-08-07 Knoell Hans Forschung Ev Die Verwendung von Terrecyclolsäure A und Terrecyclolsäure A-Derivate als neue Inhibitoren der humanen Prolyl-Oligopeptidase
AU2001270627A1 (en) * 2000-07-19 2002-01-30 F. Hoffmann-La Roche Ag Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme
FI20011466A0 (fi) * 2001-07-04 2001-07-04 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö
FI20030014A0 (fi) * 2003-01-03 2003-01-03 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä
FI20031018A0 (fi) 2003-07-04 2003-07-04 Orion Corp Parannus aivovammasta toipumiseen
JP4630192B2 (ja) 2003-09-24 2011-02-09 日本化薬株式会社 プロリルオリゴペプチダーゼ阻害剤
US7667044B2 (en) 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
ES2302473B1 (es) 2006-12-22 2009-06-12 Universidad De Barcelona Agente terapeutico para el tratamiento del desorden afectivo bipolar en mamiferos.
EP2389176A4 (en) * 2009-01-23 2012-08-01 Univ Sydney NEW THERAPY FOR METABOLISM DISEASE
EP2730571A1 (en) 2012-11-12 2014-05-14 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Also Published As

Publication number Publication date
US10611727B2 (en) 2020-04-07
EA201590942A1 (ru) 2015-10-30
CN104903314B (zh) 2018-06-05
ME02706B (me) 2017-10-20
NZ709096A (en) 2018-04-27
RS55865B1 (sr) 2017-08-31
JP2015536965A (ja) 2015-12-24
JP6203278B2 (ja) 2017-09-27
BR112015010377A8 (pt) 2018-01-16
EP2730571A1 (en) 2014-05-14
AU2013343430B2 (en) 2017-05-25
PT2917209T (pt) 2017-03-31
SI2917209T1 (sl) 2017-05-31
US20190084927A1 (en) 2019-03-21
EP2917209B1 (en) 2017-02-08
HRP20170485T1 (hr) 2017-06-02
US10125097B2 (en) 2018-11-13
PL2917209T3 (pl) 2017-09-29
AU2013343430A1 (en) 2015-07-02
KR20150082634A (ko) 2015-07-15
ES2621672T3 (es) 2017-07-04
WO2014072498A1 (en) 2014-05-15
BR112015010377A2 (pt) 2017-07-11
KR102151290B1 (ko) 2020-09-03
DK2917209T3 (en) 2017-04-18
HK1214597A1 (en) 2016-07-29
LT2917209T (lt) 2017-04-25
MX367488B (es) 2019-08-20
HUE032472T2 (en) 2017-10-30
US20160168088A1 (en) 2016-06-16
CY1118818T1 (el) 2018-01-10
EA028422B1 (ru) 2017-11-30
MX2015005931A (es) 2016-02-05
EP2917209A1 (en) 2015-09-16
CA2890042A1 (en) 2014-05-15
ZA201504269B (en) 2016-09-28
CN104903314A (zh) 2015-09-09
SMT201700202T1 (it) 2017-05-08

Similar Documents

Publication Publication Date Title
PH12014502605A1 (en) Uracyl spirooxetane nucleosides
WO2016172134A3 (en) Novel compounds
WO2014097151A3 (en) Autotaxin inhibitors
WO2014028591A3 (en) N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
CA2890042C (en) 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
IL235767A (en) Preserved pyrolidines, pharmaceuticals containing them and their uses
PH12014500137A1 (en) Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
MX2015010971A (es) Derivado novedoso de pirazol.
HK1206021A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
WO2012047017A3 (ko) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
WO2014106238A8 (en) Heterocyclic compounds and methods of use thereof
DK3045456T3 (da) Bicyklisk substituerede uraciler og anvendelse heraf
GEP20186899B (en) 6 - alkynyl pyridines as smac mimetics
HK1208678A1 (en) 3,5-diaminopyrazole kinase inhibitors
WO2013188283A8 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
WO2011039735A3 (en) Compounds with ddx3 inhibitory activity and uses thereof
WO2016178092A8 (en) C-3 novel triterpenone with c-28 reverse amide derivatives as hiv inhibitors
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
NZ702253A (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
WO2013190508A3 (en) 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives
WO2015042414A8 (en) Multicyclic compounds and methods of using same
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
WO2015124934A8 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180612